DOCKET NO.: ISIS-5207 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Brenda F. Baker, Anne B. Eldrup,

Muthiah Manoharan, Balkrishen Bhat,

Richard H. Griffey, Eric E. Swayze and

Stanley T. Crooke Confirmation No.: 5280

Application No.: 10/701,236 Group Art Unit: 1635

Filing Date: November 4, 2003 Examiner: Tracy Ann Vivlemore

For: SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND

COMPOSITIONS FOR USE IN GENE MODULATION

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

	before the mailing date of a first Office Action after the filing of request for
	continued examination under § 1.114, no additional fee is required.
	In accordance with § 1.97(c), this Information Disclosure Statement is being
	filed after the period set forth in § 1.97(b) above but before the mailing date of
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or
	before an action that otherwise closes prosecution in the application, therefore:
	Certification in Accordance with § 1.97(e) is attached; or
	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.
	In accordance with § 1.97(d), this Information Disclosure Statement is being
	filed after the mailing date of either a Final Action under § 1.113 or a Notice
	of Allowance under § 1.311 but before, or simultaneously with, the payment
	of the Issue Fee, therefore included are: Certification in Accordance with §
	1.97(e); and the submission fee of $$180.00$ as set forth in $$1.17(p)$.
\boxtimes	Copies of reference numbers 3 - 4 listed on the attached Form PTO-1449 are
	enclosed herewith.
\boxtimes	Copies of reference numbers 1 - 2 on the attached Form PTO 1449 are not
	required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).
	Copies of references - are not being submitted because
	they were previously cited by or submitted to the U.S. Patent and
	Trademark Office in patent application number , filed for
	which a claim for priority under 35 U.S.C. § 120 has been made in the
	instant application.
The r	relevance of those listed references which are not in the English language is as
follows:	

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

Date: May 11, 2007

/Leslie E. Aberman/ Leslie E. Aberman Registration No. 54,836

WOODCOCK WASHBURN LLP Cira Centre 2929 Arch Street, 12th Floor Philadelphia, PA 19104-2891 Telephone: (215) 568-3100

Telephone: (215) 568-3100 Facsimile: (215) 568-3439